Skip to main content

About Us

ElsaLys Biotech at a glance

ELSALYS BIOTECH is a specialty pharmaceutical company, part of the Mediolanum Farmaceutici Spa group, focused on innovative medicines to address haemato-oncology related life-threatening and rare diseases.

Following strategic acquisitions and targeted developments, ELSALYS is establishing an immunotherapeutic portfolio focused on niche specialty pharmaceuticals to answer unmet medical needs.

Today ELSALYS BIOTECH is conducting 3 proprietary development programs including Inolimomab (LEUKOTAC®), an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease and that is currently benefitting of cohort ATU in France for the treatment of graft-versus-host disease, corticosteroid-resistant or corticosteroid-dependent, with grade II-IV.

Our commitment is to offer essential drugs meeting Public Health needs.

Founded in 2013, ELSALYS BIOTECH is located in the heart of the European cluster Lyon Biopole, in Lyon, France.

Temporary Authorisation for Use (ATU) for inolimomab
Submission of Biologics License Application to FDA
Academic Partnerships

Management team

Dr Christine Guillen, PharmD

CEO and Co-founder

Christine Guillen co-founded ELSALYS BIOTECH in 2013.

Dr Jacques Mizrahi, PhD

Vice President R&D

Jacques Mizrahi joined ELSALYS BIOTECH in 2014.

Dr David Liens, MD

Vice President Medical Affairs

David Liens has been with ELSALYS BIOTECH since 2017.

Dr Philippe CHABERT, PhD

Chief Operating Officer

Philippe Chabert joined ELSALYS BIOTECH as COO in September 2020.


Subcribe to our newsletter

Copyright 2021 ElsaLys Biotech SA

twitter    linkedin

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.